JP2024102236A5 - - Google Patents

Download PDF

Info

Publication number
JP2024102236A5
JP2024102236A5 JP2024075101A JP2024075101A JP2024102236A5 JP 2024102236 A5 JP2024102236 A5 JP 2024102236A5 JP 2024075101 A JP2024075101 A JP 2024075101A JP 2024075101 A JP2024075101 A JP 2024075101A JP 2024102236 A5 JP2024102236 A5 JP 2024102236A5
Authority
JP
Japan
Prior art keywords
amino
methanone
dihydrofuro
methyl
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024075101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024102236A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/063540 external-priority patent/WO2022132914A1/en
Application filed filed Critical
Publication of JP2024102236A publication Critical patent/JP2024102236A/ja
Publication of JP2024102236A5 publication Critical patent/JP2024102236A5/ja
Pending legal-status Critical Current

Links

JP2024075101A 2020-12-16 2024-05-07 Prmt5阻害剤 Pending JP2024102236A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063126416P 2020-12-16 2020-12-16
US63/126,416 2020-12-16
PCT/US2021/063540 WO2022132914A1 (en) 2020-12-16 2021-12-15 Prmts inhibitors
JP2023535834A JP7487421B2 (ja) 2020-12-16 2021-12-15 Prmt5阻害剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023535834A Division JP7487421B2 (ja) 2020-12-16 2021-12-15 Prmt5阻害剤

Publications (2)

Publication Number Publication Date
JP2024102236A JP2024102236A (ja) 2024-07-30
JP2024102236A5 true JP2024102236A5 (https=) 2025-01-07

Family

ID=79927288

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023535834A Active JP7487421B2 (ja) 2020-12-16 2021-12-15 Prmt5阻害剤
JP2024075101A Pending JP2024102236A (ja) 2020-12-16 2024-05-07 Prmt5阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023535834A Active JP7487421B2 (ja) 2020-12-16 2021-12-15 Prmt5阻害剤

Country Status (17)

Country Link
US (2) US11845760B2 (https=)
EP (2) EP4263545B1 (https=)
JP (2) JP7487421B2 (https=)
KR (1) KR20230121820A (https=)
AR (1) AR124369A1 (https=)
AU (1) AU2021400942A1 (https=)
CA (1) CA3204823A1 (https=)
CL (1) CL2023001738A1 (https=)
CO (1) CO2023008167A2 (https=)
CR (1) CR20230310A (https=)
IL (1) IL303451A (https=)
JO (1) JOP20230138A1 (https=)
MX (1) MX2023007192A (https=)
PE (1) PE20231295A1 (https=)
TW (1) TW202233183A (https=)
UY (1) UY39565A (https=)
WO (1) WO2022132914A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2021086879A1 (en) 2019-10-28 2021-05-06 Tango Therapeutics, Inc. Compounds and methods of use
CN116568677A (zh) 2020-07-31 2023-08-08 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
AU2021400942A1 (en) * 2020-12-16 2023-07-06 Amgen Inc. PRMT5 inhibitors
TW202319046A (zh) * 2021-08-30 2023-05-16 美商安進公司 用於合成㖠啶衍生物及其中間體之方法
CA3255376A1 (en) * 2022-04-08 2023-10-12 Amgen Inc. CANCER TREATMENTS USING MTA-COOPERATED PRMT5 INHIBITORS
WO2024002263A1 (zh) * 2022-06-30 2024-01-04 南京明德新药研发有限公司 氨基取代的杂芳基衍生物及其应用
AU2023296592A1 (en) * 2022-07-01 2025-01-30 Cytosinlab Therapeutics Co., Ltd. Class of prmt5 inhibitors and use thereof
CN119013274A (zh) * 2022-07-26 2024-11-22 上海和誉生物医药科技有限公司 一种prmt5抑制剂及其制备方法和药学上的应用
AU2023319559B2 (en) * 2022-08-03 2026-04-16 Abbisko Therapeutics Co., Ltd. Nitrogen-containing fused three ring prmt5 inhibitor, and preparation method therefor and pharmaceutical use thereof
CN119730853A (zh) 2022-08-15 2025-03-28 阿斯利康(瑞典)有限公司 用于治疗癌症的mta协同prmt5抑制剂
JP2025529831A (ja) * 2022-08-18 2025-09-09 メッドシャイン ディスカバリー インコーポレイテッド アミド含有複素環誘導体とその使用
CN117658980A (zh) * 2022-09-08 2024-03-08 郑州同源康医药有限公司 双环类prmt5抑制剂
EP4588920A4 (en) * 2022-09-26 2026-01-28 Shanghai Apeiron Therapeutics Company Ltd NEW PRMT5 INHIBITOR AND ITS USE
IL319814A (en) * 2022-09-26 2025-05-01 Shanghai Apeiron Therapeutics Company Ltd A novel inhibitor of protein arginine methyltransferase 5 and its use
CN115677708B (zh) * 2022-10-19 2024-11-29 深圳万知达企业管理有限公司 一种吡咯并喹喔啉的制备方法
TW202440126A (zh) * 2022-11-30 2024-10-16 美商安進公司 利用mta協作的prmt5抑制劑和mat2a抑制劑之癌症治療
KR20250119589A (ko) * 2022-12-05 2025-08-07 암젠 인크 나프티리딘 화합물의 고체 형태
WO2024131901A1 (zh) * 2022-12-23 2024-06-27 深圳微芯生物科技股份有限公司 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用
CN116332856A (zh) * 2023-01-04 2023-06-27 荟达医药科技(上海)有限公司 一种4-哒嗪甲醇的合成方法
JP2026504889A (ja) 2023-01-18 2026-02-10 アンテンジーン・ディスカバリー・リミテッド Prmt5阻害化合物およびその使用
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
CN120769934A (zh) * 2023-02-28 2025-10-10 美国安进公司 用于合成萘啶衍生物及其中间体的方法
CN121241054A (zh) * 2023-04-14 2025-12-30 北京双鹤润创科技有限公司 氮杂环羰基稠环衍生物及其用途
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4700025A1 (en) 2023-04-23 2026-02-25 Suzhou Genhouse Bio Co., Ltd. Amide compound, pharmaceutical composition comprising same, and use thereof
CN121358731A (zh) * 2023-05-17 2026-01-16 四川科伦博泰生物医药股份有限公司 三并环酰胺化合物、包含其的药物组合物及其制备方法和用途
US11845749B1 (en) 2023-07-13 2023-12-19 King Faisal University Substituted pyrido[4′,3′:5,6]pyrazino[1,2-a]indoles as anticancer agents
WO2025016323A1 (zh) 2023-07-14 2025-01-23 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
CN120943832A (zh) 2023-08-02 2025-11-14 成都微芯药业有限公司 杂环炔基取代的酰胺衍生物、其制备方法及其应用
AU2024319888A1 (en) 2023-08-09 2026-02-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Heteroaryl compound, preparation method therefor, and use thereof in medicine
CN121127472A (zh) 2023-08-18 2025-12-12 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
AU2024356380A1 (en) * 2023-10-06 2026-04-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025077856A1 (en) * 2023-10-12 2025-04-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Tricyclic-carbonyl-nitrogen heterocyclic derivatives and use thereof
US20250154172A1 (en) * 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025166215A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025166274A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025190395A2 (en) * 2024-03-14 2025-09-18 Pharmaengine, Inc. Mta-cooperative prmt5 inhibitor
WO2025215153A1 (en) * 2024-04-10 2025-10-16 Ryvu Therapeutics S.A. Prmt5 inhibitors
WO2025257104A1 (en) 2024-06-10 2025-12-18 Sandvik Mining And Construction Tools Ab Diamond and cemented carbide composite material
WO2025265110A1 (en) 2024-06-21 2025-12-26 Amgen Inc. Oral pharmaceutical compositions comprising a naphthyridine compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573932B (zh) 2014-08-22 2019-07-30 默克专利股份公司 吲唑类
PL3665179T3 (pl) 2017-08-09 2021-11-29 Prelude Therapeutics, Incorporated Selektywne inhibitory metylotransferazy argininowej białek 5 (prmt5)
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833669A4 (en) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
JP7787819B2 (ja) * 2020-02-12 2025-12-17 アムジェン インコーポレイテッド 新規prmt5阻害剤
AU2021400942A1 (en) * 2020-12-16 2023-07-06 Amgen Inc. PRMT5 inhibitors

Similar Documents

Publication Publication Date Title
JP2024102236A5 (https=)
JP7487421B2 (ja) Prmt5阻害剤
KR102396930B1 (ko) 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
US11964961B2 (en) Heteroaromatic compounds and their use as dopamine D1 ligands
AU2023356612A1 (en) Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
TWI325865B (en) Pyrazolopyridine derivatives
JP6162144B2 (ja) 4,4−二置換−1,4−ジヒドロピリミジン、及びb型肝炎の処置のための医薬としてのその使用
JP2025535045A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
CN113874363A (zh) 蛋白质酪氨酸磷酸酶抑制剂
US12404261B2 (en) Compounds and compositions for treating conditions associated with cGAS
IL256964A (en) Csf-1r receptor antagonists
JP2013523884A5 (https=)
CN114945571A (zh) 环状化合物及其使用方法
TW200817375A (en) Compounds and compositions as ITPKB inhibitors
JP2024528021A (ja) 新規なparp7阻害剤及びその使用
TW201113286A (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
JP7681116B2 (ja) カルボニル置換ジアザスピロ化合物及びその使用
CN116490503A (zh) 酪蛋白激酶1δ调节剂
WO2015028848A1 (en) Bicyclic heterocyclic compounds as multi-kinase inhibitors
JPWO2019038384A5 (https=)
WO2025132946A1 (en) Phenylpyrrolidine derivatives and their use as poi-theta derivatives
WO2025255288A1 (en) Pkc-theta inhibitors, compositions, and methods of use
KR20230107542A (ko) 헤테로방향족 화합물 및 이의 용도
CN105461709A (zh) 取代脲衍生物及其在药物中的应用
RU2022107496A (ru) Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III